News | Breast Imaging | June 26, 2017

NCCN Guidelines for Chest CT in Breast Cancer Reduce False Positives, Healthcare Spending

Siteman Cancer Center study uncovered potential to significantly improve NCCN Guidelines-concordant care in patients with early-stage breast cancer

NCCN Guidelines for Chest CT in Breast Cancer Reduce False Positives, Healthcare Spending

June 26, 2017 — A recent study appears to confirm the recommendations of the National Comprehensive Cancer Network (NCCN) Guidelines panel against chest computed tomography (CT) scans in breast cancer patients asymptomatic for distant metastases. The study, conducted by researchers at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, is published in the June issue of Journal of the National Comprehensive Cancer Network (JNCCN).

According to SEER data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease. For this demographic, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) recommend standard imaging with bilateral mammography and ultrasound and, in some cases, breast magnetic resonance imaging (MRI). The NCCN Guidelines for Breast Cancer do not recommend chest computerized tomography (CT) scans in patients asymptomatic for distant metastases. Regardless, many asymptomatic patients undergo chest CT.

Using data from a prospective database, Barbara Dull, M.D., and colleagues studied records of more than 3,300 patients diagnosed with early-stage breast cancer between 1998 and 2012. They found that 11 percent of patients with stage I and more than 36 percent of patients with stage II breast cancer underwent chest CT within six months of diagnosis, despite NCCN Guidelines recommendations. Of these 683 patients, only nine were diagnosed with pulmonary metastases. However, benign pulmonary nodules were discovered in 175 patients.

“The overwhelming majority of nodules found in this study’s patient population classified as false positive results,” said Dull. “Not only do the costs of the chest CT and subsequent imaging and work-up put a cost constraint on the already burdened healthcare system, but the psychological impact of such results on a patient and their family is enormous.”

 “I hope patients and their physicians are reassured by findings like these,” added Amy Cyr, M.D., corresponding author of the study. “Chest CT and other staging studies are of extremely low yield for identifying metastases in patients with early-stage breast cancer, and even for the 1.3 percent of patients in our cohort ultimately diagnosed with pulmonary disease, many were not diagnosed because of that original CT scan, but were instead diagnosed on scans as long as two years after diagnosis, suggesting even lower utility. Unfortunately, for the 26.9 percent of patients with positive CT scans (the vast majority of which were false positives), the subsequent evaluation needed not only raises healthcare costs and anxiety, but also has the potential to delay oncologic treatment.”

According to the study, patients who underwent staging chest CT were generally younger and more likely to have unfavorable tumor markers. However, there were no statistical differences between patients diagnosed with metastases and those with false positive results.

“Even with numerous guidelines and recommendations, staging studies are routinely performed in patients with stage I and II breast cancer. Despite NCCN recommendations, many patients with asymptomatic early-stage breast cancer continue to undergo chest CT as part of their initial evaluation. Adherence to the NCCN Guidelines and other evidence-based recommendations will spare patients unnecessary testing and, in an era of increasing healthcare costs, also curb excessive spending,” said Dull.

“Notwithstanding the publicized potential risks of radiation exposure and the disputable value of chest CT in early-stage breast cancer, referring clinicians still order it, not infrequently, based on anecdotal cases, concerns regarding legal ramifications or to satisfy insistent patients. At all stages of cancer care, including at presentation, during neoadjuvant or adjuvant therapy, and with advanced disease, evidence-based guidelines are needed to help direct treating physicians and their patients in selecting appropriate and indicated imaging studies,” said Pamela J. DiPiro, M.D., Dana-Farber/Brigham and Women’s Cancer Center, in a June JNCCN commentary titled, “Evidence-Based Guidelines: Optimizing Imaging in Cancer Care.”

For more information: www.jnccn.org

Related Content

Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
Densitas Enters Partnership Agreement With TeleMammography Specialists
News | Breast Density | February 14, 2019
Breast imaging analytics company Densitas Inc. announced a new collaboration partnership with TeleMammography...
Siemens Healthineers Demonstrates Artificial Intelligence, Healthcare Digitalization at HIMSS19
News | Artificial Intelligence | February 13, 2019
February 13, 2019 — At the 2019 Healthcare Information and Management Systems Society (HIMSS) global conference and e
Hologic Launches Unifi Analytics Business Intelligence Tool
Technology | Analytics Software | February 12, 2019
Hologic Inc. announced the U.S. launch of Unifi Analytics, a business intelligence tool that allows healthcare...
Mount Sinai's Digital 3-D Mammography Van Rolls Into New York City
News | Mammography | February 11, 2019
Mount Sinai Hospital recently launched the Mount Sinai Mobile Mammography Program (MMP), bringing essential breast...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
breast density cancer awareness
News | Breast Density | February 08, 2019
Governor Michelle Lujan Grisham has signed breast density inform bill, ...
Fujifilm Launches Latest Synapse 3D Version at HIMSS 2019

The new Intravoxel Incoherent Motion (IVIM) MR application in Synapse 3D

Technology | Advanced Visualization | February 08, 2019
Fujifilm Medical Systems U.S.A. will debut the latest version of its Synapse 3D solution at the Healthcare Information...
Korean National Training Center Installs Carestream OnSight 3D Extremity System
News | Computed Tomography (CT) | February 07, 2019
Jincheon National Training Center in Jincheon, South Korea, installed a Carestream OnSight 3D Extremity System at its...
Canon Medical Debuts Alphenix 4-D CT at RSNA 2018
Technology | Angiography | February 06, 2019
Canon Medical Systems USA Inc. recently introduced a new angiography configuration featuring its Alphenix Sky + C-arm...